Omipalisib

Key Product Details

Product Description

Omipalisib is a highly potent PI 3-K inhibitor (IC₅₀ = 0.04 nM). Also inhibits mTOR (K_i = 0.18 - 0.3 nM) and DNA-PK (IC₅₀ = 0.28 nM). Induces G₁ cell cycle arrest and inhibits proliferation of some breast cancer cells lines in vitro. Reduces pAKT-S473 levels in and inhibits growth of BT474 breast cancer xenografts in mice. Orally bioavailable.

Product Specifications for Omipalisib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Omipalisib

The following data is based on the product molecular weight 505.50.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	9.89 mL	49.46 mL	98.91 mL
1 mM	1.98 mL	9.89 mL	19.78 mL
2 mM	0.99 mL	4.95 mL	9.89 mL
10 mM	0.20 mL	0.99 mL	1.98 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Knight Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med.Chem.Lett. 2010 PMID: 24900173

Product Documents for Omipalisib